Results 71 to 80 of about 2,650 (185)
TNOA Journal of Ophthalmic Science and ResearchPurpose: To compare the OCT angiography (OCTA)–derived parametric changes before and after intravitreal administration of ranibizumab and brolucizumab in patients with neovascular age-related macular degeneration (ARMD) and to compare the changes between
Sanjitha Vilma Moses +3 more
doaj +1 more source
The Journal of Clinical Pharmacology, Volume 65, Issue 7, Page 895-908, July 2025.Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley +1 more source
Gains in the current understanding of managing neovascular AMD with brolucizumab
Journal of Ophthalmic Inflammation and Infection, 2023 Background Unresolved retinal fluid and high injection burden are major challenges for patients with neovascular age-related macular degeneration. Brolucizumab addresses these challenges by providing robust vision gains and superior fluid resolution ...
Bahram Bodaghi +4 more
doaj +1 more source
Association of Polyp Regression after Loading Phase with 12-Month Outcomes of Eyes with Polypoidal Choroidal Vasculopathy [PDF]
Purpose: We compared 12-month outcomes of eyes with polypoidal choroidal vasculopathy (PCV) with or without complete regression of polyps observed one month after three monthly intravitreal administrations (loading phase) of aflibercept (2.0 mg/0.05 mL ...
00535619 +37 more
core +1 more source
iMetaOmics, Volume 2, Issue 2, June 2025.This study investigates the risk of thrombotic microangiopathy (TMA) induced by vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors in cancer therapy. Using data from the FDA Adverse Event Reporting System (FAERS), the WHO Global Database for Adverse Drug Reactions (Vigibase), and The Cancer ...
Aimin Jiang +7 more
wiley +1 more source
Scientific ReportsPachychoroid neovasculopathy (PNV) is characterized by increased choroidal thickness, choroidal hyperpermeability, and fluid accumulation. Given its distinct pathophysiology, PNV requires management with anti-VEGF therapy, as its treatment response ...
Areum Jeong +3 more
doaj +1 more source
Bilateral blindness after uneventful brolucizumab injection for macular degeneration
BMC Ophthalmology, 2022 Background We report a very severe case of bilateral panuveitis and ischemic vasculitis with possible perineural inflammation, which followed bilateral intravitreal brolucizumab administration in a patient with neovascular age-related macular ...
Ilan Barchichat +3 more
doaj +1 more source
Escherichia coli in the production of biopharmaceuticals
Biotechnology and Applied Biochemistry, Volume 72, Issue 2, Page 528-541, April 2025.Abstract Escherichia coli has shouldered a massive workload with the discovery of recombinant DNA technology. A new era began in the biopharmaceutical industry with the production of insulin, the first recombinant protein, in E. coli and its use in treating diabetes. After insulin, many biopharmaceuticals produced from E. coli have been approved by the
İbrahim İncir, Özlem Kaplan
wiley +1 more source
Brolucizumab and Platelet Activation and Reactivity [PDF]
\ua9 2025 The Author(s). Published with license by Taylor & Francis Group, LLC. Purpose: This study explores the potential interaction of brolucizumab with platelets and its effects on platelet activation and reactivity, crucial in retinal vasculitis
Bieber K +6 more
core